Therapeutic Effect of Chinese Herbal Medicine on Food Allergy (FAHF-2)
The increasing prevalence of allergic diseases in westernised countries poses a significant health problem and a tremendous burden on quality of life and healthcare expenditure. Food allergy affects as many as 6% of young children and 3% to 4% of adults. While the majority of children outgrow their allergy to milk, egg, wheat and soy, allergies to peanut, tree nuts, fish and shellfish are often life-long. Currently, there are no treatments that can cure or provide long-term remission from food allergy. Based on our preliminary studies, we hypothesise that our investigational botanical drug, FAHF-2TM, will be a safe and effective herbal therapy for food allergy.
Official Title
Investigation of the Safety of the Food Allergy Herbal Formula (FAHF-2TM) in Patients With Food Allergy – Phase 1 and Phase 1 Extension Trial.
Conditions
- Food Allergy
Study Type
Interventional
Study Design
Other, Randomised, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study.
Further Details
Primary Outcome Measures:
- Safety of FAHF-2
Secondary Outcome Measures:
- Lab studies
Study Start
December 2007
Eligibility & Criteria
- Ages Eligible for Study: 12 Years to 45 Years
- Genders Eligible for Study: Both
- Accepts Healthy Volunteers: Yes
Inclusion Criteria:
- Male and female subjects ages 12 through 45 years of age and otherwise in good health as determined by medical history and physical examination
- History of allergy to peanut, tree nut, fish or shellfish as documented by a positive skin test and/or food allergen-specific IgE level [skin prick test positive (end-point prick skin test titration performed in duplicate, one in each arm; mean wheal diameter >5 mm greater than mean of saline control; peanut, tree nut, fish or shellfish specific IgE > 0.7 kU/L)
- The subject agrees to participate in the study or the subject’s parent or legal guardian is willing and able to give written informed consent, and the paediatric subject gives assent for participation in the study.
- Females of childbearing potential must be inactive sexually or take effective birth control measures, as deemed appropriate by the investigator, for the duration of the study
Exclusion Criteria:
- Acute febrile illness (such as cold, flu, etc.) within one week before administration of study drug
- Any history of systemic disease that in the investigator’s opinion would preclude the subject from participating in this study, e.g. autoimmune disease, neoplasms, HIV or hepatitis virus infection
- Abnormal hepatic function (ALT/AST and bilirubin >1.25 x upper limit of normal)
- Abnormal bone marrow function (WBC <4 x 103/mm3; platelets <100 x 103/mm3; hgb <11 g/dl)
- Abnormal renal function (BUN and creatinine >1.25 x upper limit of normal)
- Clinically significant abnormal electrocardiogram
- Current uncontrolled moderate to severe asthma with FEV1 <80% predicted
- Participation in another experimental therapy study within 30 days of this study
- History of alcohol or drug abuse
- Currently taking antidepressant medication
- Pregnant or lactating female subjects. Females of childbearing potential will need a negative serum pregnancy test at screening to be considered for this study
Total Enrolment
18
Contact Details
Dates
Tags
Created by: